The U.S. Food and Drug Administration has approved Journey Medical's Emrosi (minocycline hydrochloride) for the treatment of ...

The FDA’s openness to a pathway for accelerated approval using biomarker-based endpoints, such as caudate atrophy, supports the potential for WVE-003 to progress rapidly through clinical trials.

The reelection of former President Donald Trump, coupled with Republicans gaining the Senate majority and poised to gain the House majority, ...

Autolus Therapeutics ( (AUTL) ) has provided an announcement. Autolus Therapeutics has achieved a pivotal milestone with the FDA’s ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...

The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & ...

We are now fully focused on preparing for the potential approval of cosibelimab and look ... the risks and uncertainties associated with the regulatory review process; uncertainties regarding the ...

Gov. Newsom has begun the process to grant a posthumous pardon to Richard “Butch” Penry, a Petaluma resident who won the ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Elon Musk's support for Trump could lead to significant policy shifts benefiting his companies. His potential role in the new ...